Chemoproteomic Profiling Reveals that Anti-Cancer Natural Product Dankastatin B Covalently Targets Mitochondrial VDAC3
B. P. Belcher, P. A. Machicao, B. Tong, E. Ho, J. Friedli, B. So, H. Bui, Y. Isobe, T. J. Maimone, D. K. Nomura
This study identifies dankastatin B as a covalent inhibitor of VDAC3 in breast cancer cells, revealing its mechanism of action through chemoproteomic profiling.
bioRxiv · Feb 11, 2023 · PreprintBiochemistry